Increased prescription rate of anti‐infective agents after diagnosis of myelodysplastic syndromes

Increased prescription rate of anti‐infective agents after diagnosis of myelodysplastic syndromes

Abstract The a priori risk for infections in patients with myelodysplastic syndromes (MDS) is unknown. This study examines prescription rates of anti‐infective agents in MDS patients before and after diagnosis, in both in‐ and outpatient settings, to provide information on infection management in cl...

Full description

Bibliographic Details
Main Authors: Johanne Rozema, Mels Hoogendoorn, Iris Potma, Inge tenSeldam, Nic J. G. M. Veeger, Robby E. Kibbelaar, Arjan A. van deLoosdrecht, Eric N. vanRoon, the HemoBase Population Registry Consortium
Format: Article
Language:English
Published: Wiley 2022-08-01
Series:eJHaem
Subjects:
anti‐infective agent
infections
myelodysplastic syndromes
population‐based
Online Access:https://doi.org/10.1002/jha2.422

Internet

https://doi.org/10.1002/jha2.422

Similar Items